Press Releases
Our press releases
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting Dec 13 2021
- Bio-Path Holdings Reports Third Quarter 2021 Financial Results Nov 12 2021
- Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021 Nov 5 2021
- Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting Nov 4 2021
- Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors Oct 27 2021
- Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients Aug 24 2021
- Bio-Path Holdings Reports Second Quarter 2021 Financial Results Aug 13 2021
- Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021 Aug 6 2021
- Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 Jun 22 2021
- Bio-Path Holdings Reports First Quarter 2021 Financial Results May 14 2021
Show More Posts
Loading...